News

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...
Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.
The results showed that semaglutide improved both short-term and long-term memory in the Alzheimer’s model mice. In a test ...
The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...
Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...
Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...
CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...
💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...
Semaglutide is the compound in the drugs Ozempic, which treats diabetes, and Wegovy, which treats obesity. Sodhi focused only on people taking Wegovy to treat overweight or obesity to avoid any ...
In a new research paper, scientists say they’ve discovered a naturally occurring hormone that might help people lose weight while avoiding the side effects commonly associated with semaglutide ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Female semaglutide users had more than a two-fold higher risk for hair loss than users of bupropion-naltrexone.